Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €89.34 EUR
Change Today -0.026 / -0.03%
Volume 1.7K
SNW On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 10:34 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SNW) Snapshot

Open
€88.79
Previous Close
€89.37
Day High
€90.36
Day Low
€88.54
52 Week High
04/13/15 - €99.17
52 Week Low
10/29/14 - €69.68
Market Cap
117.1B
Average Volume 10 Days
4.5K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
05/11/15
P/E TM
--
Dividend
€2.85
Dividend Yield
3.17%
Current Stock Chart for SANOFI (SNW)

sanofi (SNW) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi (SNW) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi (SNW) Key Developments

PENDOPHARM Enters into Distribution Agreement with Sanofi Canada

PENDOPHARM announced an agreement with Sanofi Canada concerning exclusive rights to market and distribute non-prescription Nasacort® Allergy 24HR on the Canadian market.

Sanofi Presents at BIO International Convention 2015, Jun-17-2015 10:45 AM

Sanofi Presents at BIO International Convention 2015, Jun-17-2015 10:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Tanja WEBER, VP Corporate Oncology Business Development.

Regeneron Pharmaceuticals Inc. Announces FDA Approval of Sanofi and Regeneron's Praluent(R) (Alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to three (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNW:GR €89.34 EUR -0.026

SNW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.51 USD +1.32
Amgen Inc $154.99 USD +1.47
Bayer AG €128.26 EUR +2.27
Bristol-Myers Squibb Co $67.67 USD +1.13
Novo Nordisk A/S kr372.40 DKK +7.80
View Industry Companies
 

Industry Analysis

SNW

Industry Average

Valuation SNW Industry Range
Price/Earnings 28.1x
Price/Sales 3.4x
Price/Book 2.1x
Price/Cash Flow 17.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.